抗CD20单克隆抗体（利妥昔单抗）治疗一名难治性慢性自身免疫性溶血性贫血患儿。 - Suppr | 超能文献

Anti-CD20 monoclonal antibody (rituximab) therapy in a child with refractory chronic autoimmune haemolytic anaemia.

作者信息

Kerridge I, Hann I, Ethel M, Potter M, Prentice H G

出版信息

Intern Med J. 2003 Nov;33(11):544-5. doi: 10.1046/j.1445-5994.2003.00457.x.

DOI:10.1046/j.1445-5994.2003.00457.x

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Anti-CD20 monoclonal antibody (rituximab) therapy in a child with refractory chronic autoimmune haemolytic anaemia.抗CD20单克隆抗体（利妥昔单抗）治疗一名难治性慢性自身免疫性溶血性贫血患儿。

Intern Med J. 2003 Nov;33(11):544-5. doi: 10.1046/j.1445-5994.2003.00457.x.

2

Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab).用抗CD20（利妥昔单抗）治疗难治性自身免疫性溶血性贫血。

Br J Haematol. 2001 Jul;114(1):244-5. doi: 10.1046/j.1365-2141.2001.02873-4.x.

3

Treatment of childhood autoimmune haemolytic anaemia with rituximab.利妥昔单抗治疗儿童自身免疫性溶血性贫血

Lancet. 2001 Nov 3;358(9292):1511-3. doi: 10.1016/s0140-6736(01)06573-4.

4

Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma.利妥昔单抗对一名难治性自身免疫性溶血性贫血合并CD20阴性多发性骨髓瘤患者有效。

Br J Haematol. 2003 Aug;122(4):690-1. doi: 10.1046/j.1365-2141.2003.04478.x.

5

Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma.利妥昔单抗：治疗冷凝集素及与CD20阳性、低度非霍奇金淋巴瘤相关的难治性自身免疫性溶血性贫血的一种非常有效的疗法。

Br J Haematol. 2001 Mar;112(4):1085-6. doi: 10.1046/j.1365-2141.2001.02622-3.x.

6

[Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune hemolytic anemia].用于治疗难治性自身免疫性溶血性贫血的抗CD20单克隆抗体

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Apr;15(2):425-8.

7

Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant.抗B细胞靶向免疫疗法治疗一名幼儿难治性自身免疫性溶血性贫血

Arch Dis Child. 2003 Apr;88(4):337-9. doi: 10.1136/adc.88.4.337.

8

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.在复发或难治性血栓性血小板减少性紫癜及自身免疫性溶血性贫血的标准治疗中添加利妥昔单抗可提高缓解率和无进展生存期。

Thromb Haemost. 2007 Feb;97(2):228-33. doi: 10.1160/th06-09-0499.

9

Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab.利妥昔单抗成功诱导并维持一名慢性复发性自身免疫性溶血性贫血儿童的长期缓解。

Pediatr Hematol Oncol. 2003 Oct-Nov;20(7):557-61. doi: 10.1080/08880010390232781.

10

[Rituximab instead of splenectomy in 4 children with chronic or refractory autoimmune haemolytic anaemia].4例慢性或难治性自身免疫性溶血性贫血患儿使用利妥昔单抗替代脾切除术

Ned Tijdschr Geneeskd. 2005 Oct 15;149(42):2350-4.

引用本文的文献

1

Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review.抗CD20治疗对皮质类固醇和硫唑嘌呤难治的自身免疫性溶血性贫血：一例儿科病例报告及文献综述

Case Rep Hematol. 2018 Aug 26;2018:8471073. doi: 10.1155/2018/8471073. eCollection 2018.

2

Treatment with rituximab in benign and malignant hematologic disorders in children.利妥昔单抗在儿童良性和恶性血液系统疾病中的治疗应用。

J Pediatr. 2007 Apr;150(4):338-44, 344.e1. doi: 10.1016/j.jpeds.2006.12.038.